Clinical Care Options Hepatitis - HBV via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Hepatitis - HBV' source. Sat, 16 Jan 2010 14:25:54 +0100 Highlights From AASLD 2009 http://www.medworm.com/index.php?rid=3001609&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FCCO%2520Slideset%2FAASLD_2009_Highlights.aspx CCO Slideset - Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3001609 Tue, 17 Nov 2009 00:00:00 +0100 3001609 Fixed-Dose Tenofovir/Emtricitabine Safe and Effective Option for the Treatment of Patients With Chronic Hepatitis B Infection and Decompensated Liver Disease http://www.medworm.com/index.php?rid=2965052&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F222.aspx Capsule Summary - The safety profile and virologic, biochemical, and clinical efficacy outcomes were similar among patients treated with 48 weeks of tenofovir/emtricitabine, tenofovir monotherapy, or entecavir monotherapy in this randomized phase II study. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2965052 Thu, 05 Nov 2009 16:48:00 +0100 2965052 Beyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screening, Diagnosis, and Initial Therapy http://www.medworm.com/index.php?rid=2965053&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Iceberg%2FCCO%2520Slideset%2FHBV_Iceberg_Slides.aspx CCO Slideset - Downloadable slides for use in your own noncommercial presentations highlight key data on selecting patients for HBV screening and evaluation and optimizing first-line treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2965053 Thu, 05 Nov 2009 16:13:03 +0100 2965053 HCC Risk Remains High Following at Least 12 Months of Antiviral Therapy in Cirrhotic Patients With Chronic Hepatitis B http://www.medworm.com/index.php?rid=2956491&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F137.aspx Capsule Summary - A multivariate analysis identified cirrhosis, older age, and male sex as independent predictors of hepatocellular carcinoma incidence in patients receiving at least 12 months of oral antiviral therapy, most of which was lamivudine based. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2956491 Tue, 03 Nov 2009 12:00:00 +0100 2956491 Intrahepatic cccDNA Levels at End of Treatment With Peginterferon alfa-2a Plus Adefovir Predictive of SVR in Patients With Chronic Hepatitis B http://www.medworm.com/index.php?rid=2961017&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F486.aspx Capsule Summary - Intrahepatic cccDNA levels at baseline were not prognostic for response to peginterferon alfa-2a plus adefovir therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2961017 Mon, 02 Nov 2009 17:23:09 +0100 2961017 Entecavir Associated With High Response Rates Over 36 Months in Patients With HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B http://www.medworm.com/index.php?rid=2952284&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F476.aspx Capsule Summary - Virologic response rates with entecavir were highest among patients who were previously untreated and among those with HBeAg-negative disease or low baseline HBV DNA levels; high response rates were also observed among patients with precore mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2952284 Mon, 02 Nov 2009 09:01:53 +0100 2952284 Increase in ALT to ≥ 2 Times ULN During Follow-up Correlates With Increasing Morbidity and Mortality Among HBeAg-Negative, HBsAg-Positive Individuals http://www.medworm.com/index.php?rid=2932590&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FTai-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2932590 Tue, 27 Oct 2009 00:00:00 +0100 2932590 Early Peginterferon-Induced HBeAg Loss Associated With Higher Probability of HBsAg Loss and Sustained Undetectable HBV DNA http://www.medworm.com/index.php?rid=2932589&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-AJG-2009%2FSlideset.aspx CCO Slideset - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2932589 Tue, 27 Oct 2009 00:00:00 +0100 2932589 Early Peginterferon-Induced HBeAg Loss Associated With Higher Probability of HBsAg Loss and Sustained Undetectable HBV DNA http://www.medworm.com/index.php?rid=2910258&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-AJG-2009%2FCapsule.aspx Capsule Summary - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2910258 Tue, 20 Oct 2009 00:00:00 +0100 2910258 Increase in ALT to ≥ 2 Times ULN During Follow-up Correlates With Increasing Morbidity and Mortality Among HBeAg-Negative, HBsAg-Positive Individuals http://www.medworm.com/index.php?rid=2900520&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FTai-Hepatology-2009%2FCapsule.aspx Capsule Summary - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2900520 Thu, 15 Oct 2009 00:00:00 +0100 2900520 Benefits and Risks of HBV Therapy http://www.medworm.com/index.php?rid=2676360&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FDusheiko.aspx Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2676360 Fri, 31 Jul 2009 19:40:31 +0100 2676360 Treatment of Hepatitis B: Benefits and Risks of Hepatitis B Therapy http://www.medworm.com/index.php?rid=2659236&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FDusheiko.aspx Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2659236 Fri, 31 Jul 2009 19:40:31 +0100 2659236 HBV Infection: Deciding Who and When to Treat http://www.medworm.com/index.php?rid=2589928&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FLok.aspx Learning Module - Anna S. F. Lok, MD, discusses factors to consider when evaluating patients with chronic hepatitis B infection for initiating treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2589928 Fri, 10 Jul 2009 12:00:00 +0100 2589928 Advances in HBV Treatment: 2009 http://www.medworm.com/index.php?rid=2518734&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FHBV.aspx Learning Module - Join Maria Buti, MD; Anna S. F. Lok, MD; and Patrick Marcellin, MD, as they review and discuss the latest data on the treatment of chronic HBV infection presented at the 2009 European Association for the Study of the Liver annual meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2518734 Wed, 17 Jun 2009 09:44:30 +0100 2518734 Management of Initial HBV Therapy for an HBeAg-Negative Patient http://www.medworm.com/index.php?rid=2470645&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FInteractive%2520Case%2520Challenges%2FPan%2520Case.aspx Case Challenge - Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2470645 Tue, 09 Jun 2009 12:00:00 +0100 2470645 HBV Treatment: What to Start? http://www.medworm.com/index.php?rid=2444254&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FModule%2FGish%2520Module.aspx Learning Module - Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444254 Fri, 29 May 2009 15:39:36 +0100 2444254 HBV Treatment: What to Start? http://www.medworm.com/index.php?rid=2444255&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FModule%2FGish.aspx CCO Slideset - Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own presentations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444255 Fri, 29 May 2009 00:00:00 +0100 2444255 Tenofovir Demonstrates Superior Efficacy, Similar Safety vs Adefovir in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B http://www.medworm.com/index.php?rid=2444257&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMarcellin-NEJM-2008%2FSlideset.aspx CCO Slideset - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444257 Thu, 28 May 2009 00:00:00 +0100 2444257 Managing Initial Treatment for an Asian American Patient With HBeAg-Positive Chronic Hepatitis B http://www.medworm.com/index.php?rid=2444256&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FInteractive%2520Case%2520Challenges%2FMin%2520Case.aspx Case Challenge - Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444256 Thu, 28 May 2009 00:00:00 +0100 2444256 Tenofovir Demonstrates Superior Efficacy, Similar Safety vs Adefovir in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B http://www.medworm.com/index.php?rid=2444258&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMarcellin-NEJM-2008%2FCapsule.aspx Capsule Summary - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444258 Wed, 27 May 2009 14:54:34 +0100 2444258 Early HBsAg Loss Predicts SVR in HBeAg-Negative Patients Treated With Peginterferon alfa-2a http://www.medworm.com/index.php?rid=2400576&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMoucari-Hepatology-2008%2FSlideset.aspx CCO Slideset - In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2400576 Thu, 07 May 2009 00:00:00 +0100 2400576 Early HBsAg Loss Predicts SVR in HBeAg-Negative Patients Treated With Peginterferon alfa-2a http://www.medworm.com/index.php?rid=2393052&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMoucari-Hepatology-2008%2FCapsule.aspx Capsule Summary - In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2393052 Mon, 04 May 2009 00:00:00 +0100 2393052 Equivalent Efficacy of Tenofovir/Emtricitabine vs Tenofovir Monotherapy Through Week 96 in Patients With HBV and Persistent Viremia on Adefovir http://www.medworm.com/index.php?rid=2371287&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F903.aspx Capsule Summary - Baseline adefovir and lamivudine resistance mutations did not impair subsequent Week 96 response to tenofovir +/- emtricitabine. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371287 Sun, 26 Apr 2009 14:09:21 +0100 2371287 Viral Suppression Maintained in Subset of HBeAg-Positive and HBeAg-Negative Patients Without Evidence of Genotypic Resistance After 2 Years of Telbivudine Who Continued Treatment Through 3 Years http://www.medworm.com/index.php?rid=2371288&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F911.aspx Capsule Summary - Undetectable HBV DNA at treatment Week 24 associated with improved long-term (3 years) virologic, biochemical, and serologic outcomes vs patients with detectable Week 24 HBV DNA. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371288 Sun, 26 Apr 2009 10:29:40 +0100 2371288 High Risk of Peripheral Neuropathy Associated With Telbivudine Plus Peginterferon alfa-2a vs Telbivudine Monotherapy http://www.medworm.com/index.php?rid=2371289&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F907.aspx Capsule Summary - Combination of peginterferon alfa-2a and telbivudine not recommended due to increased rates of peripheral neuropathy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371289 Sun, 26 Apr 2009 09:04:39 +0100 2371289 Tenofovir Highly Effective for the Treatment of Chronic HBV Infection in Both Cirrhotic and Noncirrhotic Patients http://www.medworm.com/index.php?rid=2366331&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F21.aspx Capsule Summary - Virologic, biochemical, and immunologic response rates were statistically similar among cirrhotic vs noncirrhotic patients treated with 96 weeks of tenofovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366331 Fri, 24 Apr 2009 16:01:20 +0100 2366331 Entecavir Resistance Rare in Nucleoside-Naive HBV Patients Through 6 Years http://www.medworm.com/index.php?rid=2366332&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F20.aspx Capsule Summary - Entecavir resistance rare in treatment-naive patients but common at Year 6 in patients with lamivudine-refractory HBV. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366332 Fri, 24 Apr 2009 15:33:27 +0100 2366332 Superior HBV Seroprotection With 2-Dose Combination HBsAg-1018 Immunostimulatory Sequence Vaccine vs Currently Approved HBV Vaccine http://www.medworm.com/index.php?rid=2518735&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F1040.aspx Capsule Summary - A higher rate of seroprotection was achieved with the HBsAg-1018 immunostimulatory sequence vs the standard HBV vaccine, even among participants aged 40-55 years. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2518735 Fri, 17 Apr 2009 00:00:00 +0100 2518735 HBsAg Levels Reduced by Telbivudine Treatment in HBeAg-Positive Patients With Chronic Hepatitis B From GLOBE Study http://www.medworm.com/index.php?rid=2366336&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F17.aspx Capsule Summary - Rapid HBsAg decline during the first year of telbivudine therapy predictive of a high rate of HBsAg clearance at Year 3. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366336 Fri, 17 Apr 2009 00:00:00 +0100 2366336 Long-term Sustained Response and HBsAg Loss After Discontinuation of 4-5 Years of Adefovir Therapy in HBeAg-Negative Patients http://www.medworm.com/index.php?rid=2366335&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F18.aspx Capsule Summary - More than one half of HBeAg-negative patients sustained response to long-term adefovir therapy for > 4 years after treatment discontinuation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366335 Fri, 17 Apr 2009 00:00:00 +0100 2366335 No Increased Risk of Birth Defects Associated With Prenatal Lamivudine or Tenofovir Exposure In Antiretroviral Pregnancy Registry Study http://www.medworm.com/index.php?rid=2366334&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F3.aspx Capsule Summary - Birth defect rates were similar with first vs second/third trimester exposure to antiretrovirals in the Antiretroviral Pregnancy Registry cohort. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366334 Fri, 17 Apr 2009 00:00:00 +0100 2366334 Entecavir Efficacy Not Affected by Previous Adefovir Treatment or Resistance in Chronic HBV–Infected Patients http://www.medworm.com/index.php?rid=2366333&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F19.aspx Capsule Summary - Virologic response rate to entecavir significantly lower in patients with lamivudine resistance vs those without. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366333 Fri, 17 Apr 2009 00:00:00 +0100 2366333 Clinical Utility of ALT in Diagnosis and Management of Chronic Hepatitis B http://www.medworm.com/index.php?rid=2252256&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNormal%2520ALT%2FInteractive%2520Virtual%2520Presentation%2FALT%2520%2C-a-%2C%2520Hepatitis%2520B.aspx CCO Virtual Presentation - W. Ray Kim, MD, discusses the importance of ALT in hepatitis B and outlines management approaches for patients with normal ALT levels. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2252256 Fri, 06 Mar 2009 00:00:00 +0100 2252256 Preventing Nucleos(t)ide Resistance in Treatment-Naive Patients http://www.medworm.com/index.php?rid=2252257&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FPreventing%2520HBV%2520Resistance%2FModules%2FPreventing%2520Resistance.aspx Learning Module - Marc G. Ghany, MD, discusses oral agents for the treatment of chronic hepatitis B, their potency, and barriers to resistance and how this impacts the selection of initial treatment regimens. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2252257 Thu, 05 Mar 2009 12:00:00 +0100 2252257 New Management Strategies for HCV Nonresponders and Relapsers http://www.medworm.com/index.php?rid=2171601&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Nonresponders%2FSlideset%2520Module%2FSlideset%2520Module.aspx Learning Module - Mitchell L. Shiffman, MD, reviews the various types of virologic response in patients treated for hepatitis C virus infection, discusses what factors are associated with better responses, and summarizes the most recent data available on various retreatment strategies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171601 Mon, 09 Feb 2009 00:00:00 +0100 2171601 Tools for the Assessment of HBV Resistance in Clinical Practice http://www.medworm.com/index.php?rid=2171600&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Resistance%2FModules%2FZoulim.aspx Learning Module - Dr. Fabien Zoulim describes assays for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171600 Mon, 09 Feb 2009 00:00:00 +0100 2171600 A Practical Guide to Management of Patients With Antiviral Drug-Resistant HBV http://www.medworm.com/index.php?rid=2171599&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FLok.aspx Learning Module - Anna S. F. Lok, MD, discusses the definitions, consequences of, and treatment strategies for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171599 Mon, 09 Feb 2009 00:00:00 +0100 2171599 Management of a Treatment-Naive, HBeAg-Positive, Asian American Patient http://www.medworm.com/index.php?rid=2171598&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Case%2520Debates%2FInteractive%2520Case%2520Challenges%2FTreatment-naive.aspx Case Challenge - Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171598 Mon, 09 Feb 2009 00:00:00 +0100 2171598 Hepatitis Journal Club: Top Clinical Articles of 2007-08 http://www.medworm.com/index.php?rid=2171597&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FHerrera.aspx Learning Module - Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171597 Mon, 09 Feb 2009 00:00:00 +0100 2171597 Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B Therapy http://www.medworm.com/index.php?rid=2171596&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tools%2FInteractive%2520Case%2520Challenges%2FTreatment%2520Naive%2520ICC.aspx Case Challenge - Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this interactive case challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171596 Mon, 09 Feb 2009 00:00:00 +0100 2171596 Management of Emergent Depression and Suicidal Ideation During HCV Therapy http://www.medworm.com/index.php?rid=2171595&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520and%2520Depression%25202008%2FInteractive%2520Case%2520Challenges%2FAlberti%2520Case.aspx Case Challenge - Join Alfredo Alberti, MD, in choosing the optimal treatment strategies for a woman who develops depressive symptoms during HCV therapy, despite the absence of symptoms at treatment baseline. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171595 Mon, 09 Feb 2009 00:00:00 +0100 2171595 Management of Hepatitis B: Understanding Treatment Candidacy and Factors for Selecting Initial Therapy http://www.medworm.com/index.php?rid=2171594&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FFirst-Line%2520Therapy%2FModule%2FFirst-Line%2520Choices.aspx Learning Module - Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171594 Mon, 09 Feb 2009 00:00:00 +0100 2171594 Mechanisms of Resistance to Anti-HBV Agents http://www.medworm.com/index.php?rid=2140347&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FPreventing%2520HBV%2520Resistance%2FModules%2FMechanisms%2520of%2520Resistance.aspx Learning Module - Maria Buti, MD, reviews the development of HBV antiviral resistance in context of the life cycle of HBV and the mechanisms of action of antiviral drugs. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2140347 Wed, 28 Jan 2009 12:00:00 +0100 2140347 HBV Highlights http://www.medworm.com/index.php?rid=2109712&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FCCO%2520Slideset%2FHBV%2520Highlights.aspx CCO Slideset - This downloadable slideset reviews key hepatitis B data from the 2008 AASLD meeting and shows how these data relate to the current management of hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2109712 Wed, 14 Jan 2009 00:00:00 +0100 2109712 Focus on Investigational HBV/HCV Agents http://www.medworm.com/index.php?rid=2080110&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents.aspx Learning Module - Join Nezam H. Afdhal, MD, FRCPI; Fred Poordad, MD; and Stefan Zeuzem, MD, as they discuss novel agents being developed for the treatment of chronic HBV and HCV infections. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2080110 Mon, 05 Jan 2009 00:00:00 +0100 2080110 HBV Expert Recap of AASLD 2008 http://www.medworm.com/index.php?rid=2080111&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHBV%2FHBV%2520ER.aspx CCO Expert Recap - Watch and listen as Nezam H. Afdhal, MD, FRCPI, reviews the key clinical data on hepatitis B investigational and approved agents presented at the 2008 AASLD meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2080111 Fri, 02 Jan 2009 00:00:00 +0100 2080111 Advances in HBV Treatment With Approved Agents http://www.medworm.com/index.php?rid=2050817&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HBV%2520Agents%2FApproved%2520HBV%2520Agents.aspx Learning Module - Join Jules L. Dienstag, MD; Robert G. Gish, MD; and Ira M. Jacobson, MD, as they discuss data presented at the 2008 AASLD Meeting on advances in the use of currently approved therapies for the treatment of chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2050817 Wed, 17 Dec 2008 00:00:00 +0100 2050817 Journal Options Slideset http://www.medworm.com/index.php?rid=2038312&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-Gastroenterol-2008%2FSlideset.aspx CCO Slideset - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2038312 Tue, 16 Dec 2008 00:00:00 +0100 2038312 HBeAg Loss Induced by Peginterferon alfa-2b ± Lamivudine Treatment Sustained Over Long-term Follow-up http://www.medworm.com/index.php?rid=2038313&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-Gastroenterol-2008%2FCapsule.aspx Capsule Summary - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2038313 Mon, 15 Dec 2008 00:00:00 +0100 2038313 HBV Patient Populations: Treating Hepatitis B in the Setting of Pregnancy http://www.medworm.com/index.php?rid=2031558&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FHBV%2520Patient%2520Populations.aspx CCO Virtual Presentation - Join Heiner Wedemeyer, MD, as he reviews HBV infection management in the setting of pregnancy and potential pregnancy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031558 Fri, 12 Dec 2008 16:06:03 +0100 2031558 Efficacy, Resistance, and Durability http://www.medworm.com/index.php?rid=2031559&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FEfficacy%2C%2520Resistance%2C%2520and%2520Durability.aspx CCO Virtual Presentation - Join Stephen Locarnini, MD, PhD, FRC (Path), as he discusses current concepts on how to best avoid antiviral resistance to initial HBV therapies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031559 Thu, 11 Dec 2008 12:00:00 +0100 2031559 Management of Suboptimal Response http://www.medworm.com/index.php?rid=2031560&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FManagement%2520of%2520Suboptimal%2520Response.aspx CCO Virtual Presentation - Join Ching-Lung Lai, MD, as he reviews strategies to identify and manage incomplete response in HBV-infected patients receiving treatment with oral antiviral therapies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031560 Wed, 10 Dec 2008 12:00:00 +0100 2031560 HBV Expert Recap of AASLD 2008 http://www.medworm.com/index.php?rid=2020801&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHBV%2FHBV%2520Slides.aspx CCO Slideset - This downloadable slideset reviews the most clinically relevant new data on hepatitis B approved and investigational therapies presented at the 2008 American Association for the Study of Liver Diseases Meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2020801 Wed, 19 Nov 2008 08:47:06 +0100 2020801 Can Hepatitis B Be Cured? http://www.medworm.com/index.php?rid=1954410&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FGhany.aspx Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1954410 Thu, 13 Nov 2008 08:38:20 +0100 1954410 Managing the Complications of Decompensated Cirrhosis http://www.medworm.com/index.php?rid=1917126&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FGarcia-Tsao.aspx Guadalupe Garcia-Tsao, MD, reviews strategies for managing the clinical complications of cirrhosis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1917126 Thu, 30 Oct 2008 07:59:04 +0100 1917126 Therapy of Chronic Hepatitis B: Who to Treat and When to Treat? A Case-Based Discussion http://www.medworm.com/index.php?rid=1899511&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FLok.aspx Anna S. F. Lok, MD, discusses factors to consider when screening patients with chronic hepatitis B infection for treatment initiation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1899511 Fri, 24 Oct 2008 08:36:28 +0100 1899511 Update on Hepatitis B Management http://www.medworm.com/index.php?rid=1814509&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FVirtual%2520Presentation%2520Programs%2FHepatitis%2520B%2520ER.aspx Daniel Shouval, MD, provides an update on the latest management strategies for patients with chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1814509 Tue, 23 Sep 2008 08:23:23 +0100 1814509 New Clinical Candidates for HBV http://www.medworm.com/index.php?rid=1540857&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Election.aspx Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1540857 Wed, 25 Jun 2008 20:28:27 +0100 1540857 Rapid, Persistent HBV DNA Suppression With Tenofovir Treatment in HBeAg-Negative Chronic Hepatitis B http://www.medworm.com/index.php?rid=1435721&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FTracks%2FHepatitis%2520B%2FCapsules%2F57.aspx Study 102 illustrated that viral suppression as a result of tenofovir therapy is sustained over 72 weeks without the emergence of resistance (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1435721 Mon, 12 May 2008 23:04:46 +0100 1435721 Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis B http://www.medworm.com/index.php?rid=1364425&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520On%2520Treatment%2FVirtual%2520Presentation%2FPresentation.aspx Join Ira M. Jacobson, MD, as he reviews on-treatment HBV guidelines including the relationships between early responses to oral anti-HBV agents and future treatment outcomes. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1364425 Fri, 11 Apr 2008 07:00:32 +0100 1364425 On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy http://www.medworm.com/index.php?rid=1329748&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520On%2520Treatment%2FInteractive%2520Case%2520Challenge%2FCase.aspx Along with Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, choose management strategies for a patient with chronic hepatitis B receiving treatment with adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1329748 Thu, 27 Mar 2008 08:44:53 +0100 1329748 Special Hepatic Issues and Populations http://www.medworm.com/index.php?rid=1250914&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FSpecial%2520Issues.aspx Expert Analysis from Robert J. Fontana, MD, Stephen A. Harrison, MD, LTC, MC, and David L. Thomas, MD, MPH. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1250914 Sat, 23 Feb 2008 08:14:22 +0100 1250914 A Case-Based Approach to Managing Resistance in Chronic HBV Infection http://www.medworm.com/index.php?rid=1232751&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FResistance%2520in%2520HBV%2FVirtual%2520Presentations%2FKeeffe.aspx Emmet B. Keeffe, MD, MACP, reviews steps to prevent, identify and manage HBV resistance to oral agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1232751 Fri, 15 Feb 2008 08:10:44 +0100 1232751 Clinical Updates in HBV Treatment http://www.medworm.com/index.php?rid=1214364&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FHBV%2520Treatment.aspx Emmet B. Keeffe, MD, MACP, Fred Poordad, MD, and Paul Martin, MD discuss data from the meeting in Boston. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1214364 Thu, 07 Feb 2008 20:12:51 +0100 1214364 Expert Recap: Clinical Updates in HBV Treatment http://www.medworm.com/index.php?rid=1151719&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FVirtual%2520Presentation%2520Programs%2FHBV%2520Treatment.aspx Watch and listen as Raymond T. Chung, MD, reviews key data and updates on hepatitis B management presented at the 2007 Boston liver disease meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1151719 Tue, 15 Jan 2008 21:19:48 +0100 1151719 Management of an HBeAg-Negative Patient With Lamivudine Resistance http://www.medworm.com/index.php?rid=1110774&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Case%2520Debates%2FInteractive%2520Case%2520Challenges%2FLamivudine%2520Resistance.aspx Emmet B. Keeffe, MD, MACP, describes treatment strategies for managing emergence of lamivudine resistance in a patient with HBeAg-negative chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1110774 Sat, 22 Dec 2007 01:05:07 +0100 1110774 Management of an HBeAg-Positive Patient on Active Antiviral Therapy Who Has Failed to Achieve a Primary Response http://www.medworm.com/index.php?rid=1102658&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Case%2520Debates%2FInteractive%2520Case%2520Challenges%2FSuboptimal%2520Response.aspx Nezam H. Afdhal, MD, FRCPI, reviews management strategies for an HBeAg-positive Asian patient with chronic HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1102658 Wed, 19 Dec 2007 01:08:04 +0100 1102658 Management of a Treatment-Naive, HBeAg-Positive, Asian American Patient http://www.medworm.com/index.php?rid=1099415&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Case%2520Debates%2FInteractive%2520Case%2520Challenges%2FTreatment-naive.aspx Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1099415 Tue, 18 Dec 2007 00:56:26 +0100 1099415 Defining HBV Resistance: Interpreting and Applying Clinical Data http://www.medworm.com/index.php?rid=1095136&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FResistance%2520in%2520HBV%2FModules%2FMartin.aspx Paul Martin, MD, reviews the treatment of patients with chronic hepatitis B, focusing on drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1095136 Sat, 15 Dec 2007 01:00:57 +0100 1095136 No Survival Benefit Found With Nucleoside Analogue Use in HBV-Related Acute Liver Failure Patients http://www.medworm.com/index.php?rid=1095135&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F95.aspx 10-year retrospective analysis suggests nucleoside analogue treatment not recommended for patients with HBV-related acute liver failure. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1095135 Sat, 15 Dec 2007 01:00:57 +0100 1095135 Correlation Between HBV DNA and Liver Disease Progression Demonstrated in Chronic HBV Patients From Northeastern Greece During 12-Year Observational Study http://www.medworm.com/index.php?rid=1095134&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F898.aspx 12-year observational study reveals that elevated HBV DNA levels are associated with liver disease progression. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1095134 Sat, 15 Dec 2007 01:00:57 +0100 1095134 GLOBE Study: Baseline and On-Treatment Predictors of Optimal Virologic Response to Telbivudine Identified for HBV Patients http://www.medworm.com/index.php?rid=1089645&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F994.aspx Among nucleos(t)ide-naive hepatitis B patients participating in GLOBE trial, predictors have been identified for favorable efficacy outcomes and low resistance rates after 2 years of treatment with telbivudine (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1089645 Thu, 13 Dec 2007 00:56:26 +0100 1089645 Approximately One Half of HBeAg-Positive Initial Nonresponders to Entecavir Achieve Undetectable HBV DNA With Extended Treatment http://www.medworm.com/index.php?rid=1089644&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F997.aspx Most HBeAg-positive nonresponders to entecavir achieved ALT normalization in ETV-901 rollover study of extended entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1089644 Thu, 13 Dec 2007 00:56:26 +0100 1089644 Entecavir Treatment in HBV Patients Achieves HBV DNA Reduction but Not HBV DNA Undetectability With Limited Response to Adefovir http://www.medworm.com/index.php?rid=1089643&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F951.aspx Entecavir reduces HBV DNA and ALT levels in patients with limited response to adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1089643 Thu, 13 Dec 2007 00:56:26 +0100 1089643 Tenofovir Significantly Decreases HBV DNA in Lamivudine- and Adefovir-Experienced Patients With No Adefovir Resistance http://www.medworm.com/index.php?rid=1089642&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F83.aspx 12 months of tenofovir suppressed HBV DNA in 90% of HBV monoinfected patients with previous lamivudine and adefovir experience but no adefovir resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1089642 Thu, 13 Dec 2007 00:56:26 +0100 1089642 Significantly Increased Risk of HCC in Chronic Hepatitis B HBsAg-Positive Patients With HBV DNA less than 104 copies/mL vs HBsAg-Seronegative Patients http://www.medworm.com/index.php?rid=1086894&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F907.aspx HBsAg-positive patients with detectable HBV DNA less than 104 copies/mL have significantly increased risk of developing HCC than those with undetectable HBV DNA (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1086894 Wed, 12 Dec 2007 00:55:39 +0100 1086894 Tenofovir Demonstrates Significant Anti-HBV Activity in Adefovir-Resistant Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=1083681&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F960.aspx Complete virologic suppression achieved in adefovir-resistant chronic hepatitis B patients following tenofovir therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1083681 Tue, 11 Dec 2007 00:53:54 +0100 1083681 Trajectory Modeling of REVEAL HBV DNA Subgroups Demonstrates That Increased Levels Over Time Associated With Increased HCC Risk http://www.medworm.com/index.php?rid=1071797&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F906.aspx Trajectory modeling of REVEAL data illustrates that changes in HBV DNA levels over time can predict the risk of developing HCC (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1071797 Thu, 06 Dec 2007 00:52:32 +0100 1071797 High HBsAg Seroconversion Rate Observed Among HBeAg-Positive Patients Who Achieved SVR to Standard Interferon Associated With Excellent Histologic Outcomes http://www.medworm.com/index.php?rid=1066678&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F991.aspx Long-term study reveals that interferon-based HBV therapy associated with significant HBsAg seroconversion rate and histologic improvements (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1066678 Tue, 04 Dec 2007 00:54:14 +0100 1066678 HBV DNA Level and Subgenotype as HCC Predictors in Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=1061915&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F903.aspx High HBV DNA level and subgenotype Ce associated with higher risk of HCC (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1061915 Sat, 01 Dec 2007 00:50:35 +0100 1061915 Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Positive HBV Patients http://www.medworm.com/index.php?rid=1059303&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2FLB6.aspx Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-positive chronic hepatitis B cohort (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1059303 Fri, 30 Nov 2007 00:56:08 +0100 1059303 Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Negative HBV Patients http://www.medworm.com/index.php?rid=1059302&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2FLB2.aspx Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-negative chronic hepatitis B cohort (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1059302 Fri, 30 Nov 2007 00:56:08 +0100 1059302 Preemptive Lamivudine Protective Against HBV-Related Morbidity and Mortality in HBsAg-Positive Cancer Patients Receiving Chemotherapy http://www.medworm.com/index.php?rid=1055453&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F945.aspx Meta-analysis of studies of preemptive lamivudine treatment in chemotherapy treated HBsAg-positive cancer patients shows a 5-fold reduction in risk of mortality. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1055453 Wed, 28 Nov 2007 13:12:26 +0100 1055453 Hepatic Steatosis in HBV-Infected Individuals Related to Host Factors, Not Viral Factors http://www.medworm.com/index.php?rid=1055452&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F921.aspx Metabolic intervention may be warranted for hepatic steatosis in HBV patients as it is associated with factors such as body mass index, cholesterol levels, and serum triglycerides. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1055452 Wed, 28 Nov 2007 13:12:26 +0100 1055452 HBV Antiviral Resistance Patterns in HBV Mirror Prescription Trends http://www.medworm.com/index.php?rid=1036416&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F954.aspx Increasing use of entecavir and adefovir in the treatment of chronic hepatitis B accompanied by increased incidence of associated resistance mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1036416 Tue, 20 Nov 2007 00:52:08 +0100 1036416 Long-term HBV DNA Suppression Achieved With Entecavir in Nucleoside-Naive HBeAg-Positive Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=1036415&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FHBV%2520Treatment%2FCapsules%2F938.aspx At 192 weeks, 91% of entecavir-treated HBeAg-positive, nucleoside-naive patients on therapy had undetectable HBV DNA. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1036415 Tue, 20 Nov 2007 00:52:08 +0100 1036415 Development of Model for End-Stage Liver Disease Improved Graft and Overall Survival Rates After Liver Transplantation in HCC Patients http://www.medworm.com/index.php?rid=1020672&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F598.aspx 3-year graft and survival rates following liver transplant in HCC patients with and without HCV infection improved after development of MELD (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1020672 Tue, 13 Nov 2007 01:03:41 +0100 1020672 Substitution of HBIg With ADV in HBV Patients Following Liver Transplantation Receiving LAM and HBIg Prophylaxis http://www.medworm.com/index.php?rid=1020671&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202007%2FTracks%2FSpecial%2520Issues%2FCapsules%2F11.aspx Adefovir suitable and cost-effective replacement for HBIg in LAM-based prophylaxis after liver transplantation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1020671 Tue, 13 Nov 2007 01:03:41 +0100 1020671 Case: Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B Therapy http://www.medworm.com/index.php?rid=1010108&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tools%2FInteractive%2520Case%2520Challenges%2FTreatment%2520Naive%2520ICC.aspx Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this interactive case challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1010108 Wed, 07 Nov 2007 13:16:51 +0100 1010108 Virologic Monitoring in Hepatitis B: Tools for Determining Treatment Candidacy and Response http://www.medworm.com/index.php?rid=1010107&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tools%2FModule%2FVirologic%2520Tools.aspx Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, discusses the importance of virologic tools, with a focus on HBV DNA monitoring, for deciding when to treat and evaluating on-treatment response to oral HBV agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1010107 Wed, 07 Nov 2007 13:16:51 +0100 1010107 Case: Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B Therapy http://www.medworm.com/index.php?rid=987921&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tools%2FInteractive%2520Case%2520Challenge%2FTreatment%2520Naive%2520ICC.aspx Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this interactive case challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=987921 Mon, 29 Oct 2007 23:57:15 +0100 987921 STACCATO Data Indicate Structured Treatment Interruption in HIV/HBV-Coinfected Patients Can Lead to HBV Viremia and Transaminase Elevations http://www.medworm.com/index.php?rid=920622&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHIV%2FConference%2520Coverage%2FChicago%25202007%2FTracks%2FHighlights%2FCapsules%2FH1736a.aspx Progression of hepatitis B infection associated with structured treatment interruption in Thai STACCATO trial. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=920622 Tue, 02 Oct 2007 23:54:11 +0100 920622 Treatment of Hepatitis B Virus Infection in Special Populations http://www.medworm.com/index.php?rid=810498&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FTerrault.aspx Norah Terrault, MD, MPH, discusses the management of hepatitis B virus (HBV) in special populations, including pregnant women, patients undergoing chemotherapy and HIV-infected individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=810498 Tue, 21 Aug 2007 00:18:37 +0100 810498 A Practical Guide to Management of Patients With Antiviral Drug-Resistant HBV http://www.medworm.com/index.php?rid=805139&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FLok.aspx Anna S. F. Lok, MD, discusses the definitions, consequences of, and treatment strategies for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=805139 Fri, 17 Aug 2007 23:57:01 +0100 805139 HBV: 2007 Treatment Overview http://www.medworm.com/index.php?rid=803121&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FKeeffe.aspx Emmet B. Keeffe, MD, MACP, reviews current hepatitis B virus treatment practices including when to initiate and when to stop therapy, available therapies, and potential future treatment options. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=803121 Fri, 17 Aug 2007 00:32:34 +0100 803121 Best of Hepatitis 2007: Top Findings in Viral Hepatitis http://www.medworm.com/index.php?rid=798635&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FAlter.aspx Harvey J. Alter, MD, MACP, discusses the top findings in viral hepatitis for the year 2007. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=798635 Wed, 15 Aug 2007 00:16:19 +0100 798635 Epidemiology and Natural History of HBV Infection http://www.medworm.com/index.php?rid=790066&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FMartin.aspx Paul Martin, MD, reviews the epidemiology and natural history of HBV infection with particular focus on the differential course of the disease for individuals infected via vertical vs horizontal transmission. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=790066 Fri, 10 Aug 2007 00:00:34 +0100 790066 Growing Pains: Obesity, Bariatric Surgery, and Nonalcoholic Fatty Liver Disease http://www.medworm.com/index.php?rid=782370&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FSanyal.aspx Arun J. Sanyal, MBBS, MD, FACP, reviews the clinical features of nonalcoholic liver disease and discusses optimal management strategies and emerging treatments for nonalcoholic steatohepatitis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=782370 Mon, 06 Aug 2007 23:52:24 +0100 782370 Choosing First-Line Therapy in Chronic Hepatitis B http://www.medworm.com/index.php?rid=750954&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FFirst-Line%2520Therapy%2FModule%2FFirst-Line%2520Choices.aspx Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=750954 Mon, 23 Jul 2007 23:59:24 +0100 750954 The Epidemic of Hepatocellular Carcinoma: Diagnosis and Therapy http://www.medworm.com/index.php?rid=746258&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FDavis.aspx Gary L. Davis, MD, reviews the epidemiology of hepatocelluar carcinoma and provides strategies for the diagnosis and management of this condition. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=746258 Sat, 21 Jul 2007 00:04:51 +0100 746258 Expert Analysis: Advances in HBV Treatment: 2007 http://www.medworm.com/index.php?rid=715502&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FTracks%2FAdvances%2520in%2520HBV%2FAdvances.aspx Adrian M. Di Bisceglie, MD, FACP, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, and Daniel Shouval, MD review new data from the EASL 2007 meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=715502 Fri, 06 Jul 2007 05:46:26 +0100 715502 Treatment of an HBeAg-Negative 47-Year-Old Man Presenting Following Routine Screening for Hepatitis B http://www.medworm.com/index.php?rid=705136&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FFirst-Line%2520Therapy%2FInteractive%2520Case%2520Challenges%2FHBeAg-Negative%2520Patient.aspx Test your ability to manage frontline treatment of an asymptomatic 47-year-old Asian male with chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=705136 Sat, 30 Jun 2007 02:35:32 +0100 705136 Highlight on Special Hepatic Issues and Populations http://www.medworm.com/index.php?rid=685856&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FTracks%2FSpecial%2520Issues%2FSpecial.aspx Nezam H. Afdhal, MD, FRCPI, Kris V. Kowdley, MD, FACP, and Josep M. Llovet, MD discuss data from EASL 2007. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=685856 Thu, 21 Jun 2007 11:25:02 +0100 685856 Expert Analysis: Hepatitis and Opportunistic Diseases http://www.medworm.com/index.php?rid=642845&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHIV%2FConference%2520Coverage%2FRetroviruses%25202007%2FTracks%2FCoinfection%2FCoinfection.aspx Richard E. Chaisson, MD, Bruce Polsky, MD, and Jrgen K. Rockstroh, MD, discuss new data from the meeting in Los Angeles. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=642845 Wed, 30 May 2007 12:32:00 +0100 642845 Phase III Data Suggest That Chronic Hepatitis B Patients Can Still Have Significant Liver Disease Despite ALT less than 2 x ULN http://www.medworm.com/index.php?rid=634456&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F483.aspx%3FTrack%3DAdvances+in+HBV Nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection can have significant liver disease despite ALT less than 2 x upper limit of normal. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=634456 Sun, 27 May 2007 00:08:20 +0100 634456 Modeling Based on Clinical and Laboratory Values Successful in Predicting Mild Fibrosis in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=634455&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F514.aspx%3FTrack%3DAdvances+in+HBV Predictive modeling based on clinical and laboratory values could reduce need for liver biopsy to identify mild liver fibrosis in HBV patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=634455 Sun, 27 May 2007 00:08:20 +0100 634455 Nucleos(t)ide Analogue Resistance Pathways and Secondary Compensatory Mutations Identified in Chronic Hepatitis B http://www.medworm.com/index.php?rid=630592&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F505.aspx%3FTrack%3DAdvances+in+HBV Lab-based study suggests 2 main pathways for nucleos(t)ide analogue resistance with currently available therapies for hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=630592 Wed, 23 May 2007 11:16:30 +0100 630592 No Long-term Benefit of Overlapping Lamivudine and Adefovir Prior to Adefovir Monotherapy in Korean Patients With Lamivudine-Resistant HBV http://www.medworm.com/index.php?rid=630591&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F503.aspx%3FTrack%3DAdvances+in+HBV Overlapping Lamivudine and Adefovir in Patients with Lamivudine-Resistant HBV Before switch to Adefovir Monotherapy Not Beneficial in Korean Study. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=630591 Wed, 23 May 2007 11:16:30 +0100 630591 Week 24 Interim Analysis During Treatment Shows Greater HBV DNA Suppression With Peginterferon alfa-2a Plus Adefovir vs Peginterferon alfa-2a Alone in HBV Patients http://www.medworm.com/index.php?rid=621192&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F54.aspx%3FTrack%3DAdvances+in+HBV Combination peginterferon alfa-2a and adefovir treatment results in more patients achieving undetectable HBV DNA by Week 24 vs peginterferon alfa-2a alone in HBeAg-negative HBV patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=621192 Sun, 20 May 2007 13:50:10 +0100 621192 Peginterferon alfa-2a Lamivudine Associated With Higher Rates of Prolonged Biochemical and Antiviral Response Than Lamivudine Alone in HBeAg-Negative Chronic Hepatitis B Patients 3 Years Posttreatment http://www.medworm.com/index.php?rid=621191&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F53.aspx%3FTrack%3DAdvances+in+HBV Durable Response achieved from 1-3 Years Posttreatment Peginterferon alfa-2a Lamivudine in HBeAg-Negative Chronic Hepatitis B Patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=621191 Sun, 20 May 2007 13:50:10 +0100 621191 HBV Patients Treated With Lamivudine and Experiencing a Suboptimal Response Benefit More From a Switch to Telbivudine Than Continued Lamivudine Treatment http://www.medworm.com/index.php?rid=606257&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F516.aspx%3FTrack%3DAdvances+in+HBV Switching to telbivudine may offer additional viral reduction for HBV patients who have experienced a suboptimal response to lamivudine therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606257 Thu, 17 May 2007 22:54:09 +0100 606257 Magnetic Resonance Elastography Noninvasive Diagnostic Tool for Hepatic Fibrosis http://www.medworm.com/index.php?rid=606256&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F109.aspx%3FTrack%3DSpecial+Issues Magnetic resonance elastography proves to be a useful noninvasive tool for identifying liver fibrosis but not steatosis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606256 Thu, 17 May 2007 22:54:09 +0100 606256 FibroScan Identified High Incidence of Fibrosis, Correlated With Biochemical Liver Disease Measures, in Large Chronic HBV-Infected Population http://www.medworm.com/index.php?rid=606255&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F478.aspx%3FTrack%3DAdvances+in+HBV High prevalence of fibrosis identified in large, HBV-infected population using FibroScan. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606255 Thu, 17 May 2007 22:54:09 +0100 606255 Entecavir Associated With Greater HBV DNA Reduction vs Adefovir at Year 1 in Treatment-Naive HBeAg-Positive Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=606254&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F49.aspx%3FTrack%3DAdvances+in+HBV In the head-to-head EARLY trial, entecavir is superior to adefovir at reducing HBV DNA levels in HBeAg-positive patients beginning at Day 10. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606254 Thu, 17 May 2007 22:54:09 +0100 606254 Long-term Study of HBeAg-Positive Italian Patients With Chronic Hepatitis B Reveals Prognostic Factors for Mortality http://www.medworm.com/index.php?rid=606253&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F477.aspx%3FTrack%3DAdvances+in+HBV Risk of liver-related death strongly associated with sustained disease activity and high level of HBV replication in untreated Italian cohort of chronic hepatitis B patients independent of HBeAg status. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606253 Thu, 17 May 2007 22:54:09 +0100 606253 9-Year Follow-up of Long-term Lamivudine Therapy in CHB Patients Demonstrates Full Viral Suppression During First Year Predictive of Overall Treatment Response http://www.medworm.com/index.php?rid=606252&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F521.aspx%3FTrack%3DAdvances+in+HBV New cases of resistance did not develop during 6-9 years of continual lamivudine therapy in patients with chronic HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606252 Thu, 17 May 2007 22:54:09 +0100 606252 Long-term Lamivudine Therapy With or Without Adefovir Improves Outcome of EVs in HBeAg-Negative Patients With Cirrhosis http://www.medworm.com/index.php?rid=606251&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F496.aspx%3FTrack%3DAdvances+in+HBV Clinical resistance to lamivudine and adefovir associated with progression of EVs during 6 years of follow-up. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606251 Thu, 17 May 2007 22:54:09 +0100 606251 GLOBE Study: Add or Switch to Adefovir a Viable Salvage Option for Telbivudine-Treated Patients Exhibiting Virologic Breakthrough http://www.medworm.com/index.php?rid=606250&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F493.aspx%3FTrack%3DAdvances+in+HBV In small analysis, adefovir alone or together with telbivudine was able to rescue virologic breakthrough occurring during telbivudine monotherapy; study not powered to compare 2 regimens. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606250 Thu, 17 May 2007 22:54:09 +0100 606250 Entecavir Maintains High Genetic Barrier to Resistance Over 4 Years of Treatment in Nucleoside-Naive Patients http://www.medworm.com/index.php?rid=606249&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F781.aspx%3FTrack%3DAdvances+in+HBV Genetic barrier to entecavir resistance significantly lower in lamivudine-refractory HBV patients due to presence of viral variants. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606249 Thu, 17 May 2007 22:54:09 +0100 606249 HBeAg Response Sustained in Most Patients Treated With Telbivudine or Lamivudine in GLOBE Trial http://www.medworm.com/index.php?rid=606248&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F58.aspx%3FTrack%3DAdvances+in+HBV More than 80% of patients treated with telbivudine or lamivudine for = 1 year in GLOBE trial sustained HBeAg response after treatment discontinuation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=606248 Thu, 17 May 2007 22:54:09 +0100 606248 Improved Survival for Acute Liver Failure Patients After 1996 due to Fewer HBV Cases and Earlier Admission to ICU http://www.medworm.com/index.php?rid=580229&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F36.aspx%3FTrack%3DSpecial+Issues Improved care and relatively milder course associated with acetaminophen-associated vs HBV-related acute liver failure jointly responsible for better rates of survival over past decade. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=580229 Tue, 01 May 2007 06:55:01 +0100 580229 Radiologic Imaging Accurately Identifies Hypervascular Lesions With, but not Without, Washout in Cirrhotic Individuals Awaiting Liver Transplantation http://www.medworm.com/index.php?rid=580228&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F84.aspx%3FTrack%3DSpecial+Issues Hypervascular-only lesions = 10 mm and nonhypervascular lesions = 20 mm not accurately identified by radiologic imaging methods. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=580228 Tue, 01 May 2007 06:55:01 +0100 580228 Long-term Treatment With V2 Receptor Antagonist Satavaptan Effective for Managing Hyponatremia in Patients With Cirrhosis http://www.medworm.com/index.php?rid=580227&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F90.aspx%3FTrack%3DSpecial+Issues Satavaptan, a V2 receptor antagonist, effectively improved hyponatremia and ascites in patients with cirrhosis during long-term use. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=580227 Tue, 01 May 2007 06:55:01 +0100 580227 Nomograms Developed From Patient and Viral Data From the REVEAL Study Predict Risk for HCC in Chronically HBV-Infected Patients http://www.medworm.com/index.php?rid=580226&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F475.aspx%3FTrack%3DSpecial+Issues Nomograms accurately predict 5- and 10-year risk predictions for hepatocellular carcinoma in HBV-infected patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=580226 Tue, 01 May 2007 06:55:01 +0100 580226 Study Suggests Depletion of CD4+CD25+ Regulatory T Cells Dramatically Improves Antitumor Immunity Induced by NY-ESO-1b Peptide Vaccine http://www.medworm.com/index.php?rid=565143&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F277.aspx%3FTrack%3DSpecial+Issues Efficacy of antitumor NY-ESO-1b peptide vaccine to prevent HCC may be enhanced by depletion of CD4+CD25+ regulatory T cells. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=565143 Tue, 24 Apr 2007 07:00:05 +0100 565143 FibroScan Able to Determine Liver Fibrosis Stage in Patients With Histologic Evidence of NAFLD http://www.medworm.com/index.php?rid=565142&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBarcelona%25202007%2FCapsules%2F730.aspx%3FTrack%3DSpecial+Issues Compared with the APRI and Forns index, FibroScan was superior at identifying F2-F4 fibrosis stage in patients with NAFLD. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=565142 Tue, 24 Apr 2007 07:00:05 +0100 565142 CPG 7909 Adjuvant Improves Immunogenic Response to Hepatitis B Vaccine in HIV-Infected Individuals http://www.medworm.com/index.php?rid=494003&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHIV%2FConference%2520Coverage%2FRetroviruses%25202007%2FCapsules%2F134.aspx%3FTrack%3DCoinfection Adjuvant CPG 7909 combined with hepatitis B vaccine in HIV-infected patients results in higher HBsAg antibody titers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=494003 Fri, 23 Mar 2007 18:35:01 +0100 494003 The Anti-HBV Drug Entecavir Inhibits HIV-1 Replication and Can Select For M184V http://www.medworm.com/index.php?rid=477540&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHIV%2FConference%2520Coverage%2FRetroviruses%25202007%2FCapsules%2F136LB.aspx%3FTrack%3DCoinfection Study suggests entecavir should not be used in HIV/HBV-coinfected patients who are not receiving HAART. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=477540 Sat, 17 Mar 2007 13:35:02 +0100 477540 Higher Incidence of Liver Transplant Complications Among Living Donor Recipients Compared With Deceased Donor Recipients http://www.medworm.com/index.php?rid=313309&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F648.aspx%3FTrack%3DSpecial+Issues Higher incidence of liver transplant complications among living donor recipients compared with deceased donor recipients likely due to lack of surgical experience. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=313309 Mon, 05 Feb 2007 13:55:01 +0100 313309 Management of an HBeAg-Positive Patient With Borderline-Normal ALT and Family History of Liver Cancer http://www.medworm.com/index.php?rid=397152&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520Paradigm%2520for%2520HBV%2FInteractive%2520Case%2520Challenges%2Fmartin.aspx Paul Martin, MD, discusses management decisions for a patient with borderline normal ALT, a family history of hepatocellular carcinoma, and HBeAg-positive serostatus. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=397152 Mon, 05 Feb 2007 08:20:02 +0100 397152 Expert Analysis: Clinical Updates in HBV Treatment http://www.medworm.com/index.php?rid=397150&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FTracks%2FHBV%2520Treatment%2FHBV%2520Treatment.aspx Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, Robert G. Gish, MD, and Marion G. Peters, MD review key clinical data from the meeting in Boston. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=397150 Mon, 05 Feb 2007 08:20:02 +0100 397150 Interactive Case Challenges: Management of an HBeAg-Negative Patient With Cirrhosis and Elevated Alanine Aminotransferase http://www.medworm.com/index.php?rid=384112&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520Paradigm%2520for%2520HBV%2FInteractive%2520Case%2520Challenges%2Fgish.aspx Robert G. Gish, MD, describes the management of a recently diagnosed HBeAg-negative patient presenting with elevated ALT. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=384112 Mon, 05 Feb 2007 08:20:02 +0100 384112 Management of Resistance: Implications for Treatment Choice http://www.medworm.com/index.php?rid=384111&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520Paradigm%2520for%2520HBV%2FModules%2Fpawlotsky.aspx Jean-Michel Pawlotsky, MD, PhD, reviews clinical strategies for preventing and managing drug resistance in patients with chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=384111 Mon, 05 Feb 2007 08:20:02 +0100 384111 New Measures of Treatment Success: Recent Data on Potency and On-Treatment Response http://www.medworm.com/index.php?rid=364909&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520Paradigm%2520for%2520HBV%2FModules%2Fgish.aspx Robert G. Gish, MD, discusses the latest clinical evidence regarding the importance of drug potency and long-term therapy in achieving optimal outcomes in the treatment of chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=364909 Mon, 05 Feb 2007 08:20:02 +0100 364909 Understanding HBV: Viral Load and Disease Progression http://www.medworm.com/index.php?rid=364908&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520Paradigm%2520for%2520HBV%2FModules%2Flai.aspx Ching-Lung Lai, MD, discusses data indicating the importance of HBV DNA levels in disease progression, and the potential mechanisms underlying this relationship. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=364908 Mon, 05 Feb 2007 08:20:02 +0100 364908 Benefits of 4-5 Years of Treatment With Adefovir Sustained Following Treatment Cessation in Majority of HBeAg-Negative Patients With No Adefovir Resistance http://www.medworm.com/index.php?rid=352313&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F114.aspx%3FTrack%3DHBV+Treatment 22 months after cessation of 4-5 years of adefovir treatment in HBeAg-negative patients, ALT levels remain normalized in majority of patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=352313 Mon, 05 Feb 2007 08:20:02 +0100 352313 Correlation Between Viral Replication, Resistance, and Rebound May Explain Specific Subset of Mutations in Entecavir-Resistant HBV http://www.medworm.com/index.php?rid=352312&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F173.aspx%3FTrack%3DHBV+Treatment Viral replication, resistance, and rebound associated with small subset of entecavir-resistance mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=352312 Mon, 05 Feb 2007 08:20:02 +0100 352312 Greater Virologic Response to Telbivudine Compared With Adefovir at 52 Weeks in HBeAg-Positive Chronic Hepatitis B Patients http://www.medworm.com/index.php?rid=352311&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F1005.aspx%3FTrack%3DHBV+Treatment Switching from adefovir to telbivudine at 24 weeks resulted in comparable HBV DNA levels at 52 weeks vs 52 weeks of continuous telbivudine therapy in HBeAg-Positive Chronic Hepatitis B Patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=352311 Mon, 05 Feb 2007 08:20:02 +0100 352311 Presence of Mutations Conferring Resistance to Entecavir and Lamivudine Detected in HBV-Infected Patients Before and During Treatment With Lamivudine http://www.medworm.com/index.php?rid=346155&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F966.aspx%3FTrack%3DHBV+Treatment A small proportion of patients possess mutations conferring entecavir and lamivudine resistance prior to and during lamivudine therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=346155 Mon, 05 Feb 2007 08:20:02 +0100 346155 Patients With Undetectable Viremia, HBeAg Loss, and HBe Seroconversion at Week 24 Associated with HBsAg Loss by Week 120 http://www.medworm.com/index.php?rid=346154&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F992.aspx%3FTrack%3DHBV+Treatment HBsAg loss is predictive of excellent prognosis but uncommon in HBV patients treated with lamivudine or entecavir (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=346154 Mon, 05 Feb 2007 08:20:02 +0100 346154 Adding Adefovir to Lamivudine Less Likely to Result in Viral Breakthrough or Resistance Than Switch to Adefovir Monotherapy for Patients With Lamivudine-Resistant HBV http://www.medworm.com/index.php?rid=342162&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2FLB5.aspx%3FTrack%3DHBV+Treatment In patients failing lamivudine monotherapy, adding adefovir results in more favorable virologic outcomes than switching to adefovir monotherapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=342162 Mon, 05 Feb 2007 08:20:02 +0100 342162 Rapidity and Magnitude of HBV DNA Suppression With Antiviral Therapy Key Factor in T-Cell Reactivity for HBeAg-Positive Patients http://www.medworm.com/index.php?rid=342161&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F967.aspx%3FTrack%3DHBV+Treatment Enhanced T-cell reactivity was observed concurrent with rapid and profound HBV DNA suppression in HBeAg-positive patients with chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=342161 Mon, 05 Feb 2007 08:20:02 +0100 342161 HBV DNA Levels Following 4 Weeks of Treatment Predictive of Long-term Response to Lamivudine http://www.medworm.com/index.php?rid=339696&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F991.aspx%3FTrack%3DHBV+Treatment Patients with HBV DNA levels less than 4 log10 copies/mL after 4 weeks of lamivudine treatment have increased probability of favorable extended virologic response. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=339696 Mon, 05 Feb 2007 08:20:02 +0100 339696 Virologic Suppression in Patients Chronically Infected With HBeAg-Negative HBV Sustained for 2 Years Following 48 Weeks of Peginterferon Alfa-2a Treatment http://www.medworm.com/index.php?rid=339695&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F972.aspx%3FTrack%3DHBV+Treatment Continued virologic suppression in some HBeAg-negative patients suggests 48 weeks of peginterferon alfa-2a treatment can provide lasting benefits (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=339695 Mon, 05 Feb 2007 08:20:02 +0100 339695 Noninvasive FibroTest and FibroScan Tests Reliably Exclude Clinically Significant Fibrosis in Inactive HBV Carriers http://www.medworm.com/index.php?rid=339694&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F809.aspx%3FTrack%3DHBV+Treatment The "FibroTest" and "FibroScan" noninvasive techniques for monitoring liver fibrosis can consistently exclude significant fibrosis in most inactive HBV carriers, for whom liver biopsy is contraindicated. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=339694 Mon, 05 Feb 2007 08:20:02 +0100 339694 Adding Adefovir to Lamivudine More Effective at Suppressing HBV DNA Than Switching to Adefovir in Individuals With Lamivudine-Resistance and High Viral Load http://www.medworm.com/index.php?rid=329805&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F113.aspx%3FTrack%3DHBV+Treatment Addition of adefovir to ongoing lamivudine more effective at achieving virologic suppression than switch to adefovir monotherapy in HBV-infected individuals with high viral load following development of lamivudine resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=329805 Mon, 05 Feb 2007 08:20:02 +0100 329805 Risk of Entecavir Resistance Remains Minimal in Treatment-Naive Patients, Increases Over Time Among Lamivudine-Refractory Patients http://www.medworm.com/index.php?rid=329804&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBoston%25202006%2FCapsules%2F110.aspx%3FTrack%3DHBV+Treatment Among HBV patients resistant to lamivudine, entecavir resistance becomes more common beyond 2 years of treatment, while genotypic resistance in treatment-naive individuals remains at ~ 1%. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=329804 Mon, 05 Feb 2007 08:20:02 +0100 329804